Feature | September 22, 2014

VADs Gaining Popularity, But Artificial Hearts Remain the Ideal, Says GlobalData Analyst

Despite reimbursement limitations prohibiting significant sales, ‘patients considering replacement pumps often have no alternatives

VADs Gain Popularity Artificial Hearts Remain Ideal GlobalData

September 22, 2014 — Robert Littlefield, MSc, GlobalData's senior analyst covering Medical Devices, said:

“Since the first implantation of the Jarvik 7 in 1982, artificial heart devices have evolved significantly in size, design and power usage, but many problems related to sealing, mechanical function, electrical sensing and reliability still persist. While newer devices, such as the Carmat pump, which was recently implanted into a second patient in France, utilize next-generation proprietary membrane materials and advanced motors, many of the same faults regarding longevity and durability continue to plague these products.

“Although several large market players have developed devices, including the Abiomed AbioCor and the Syncardia Total Artificial Heart, reimbursement limitations have prohibited significant sales. However, given the lack of available heart transplants, patients considering replacement pumps often have no alternatives. As a result, and despite the setbacks and low cost-effectiveness of these devices, GlobalData expects that this market will continue to grow from roughly $27 million in 2013 to more than $67 million by 2020, at a Compound Annual Growth Rate (CAGR) of 13%.

“As total artificial hearts only fit in around 20 percent of women and even fewer children, we also foresee a future for other cardiac assist devices that aid, but do not replace, the heart’s function. Ventricular assist devices (VADs), including the Thoratec HeartMate II and the Abiomed Impella, are much smaller than artificial hearts, and can therefore be implanted in a broader set of patients.

“Clinical studies have shown that VAD implantation earlier in a patient’s heart failure progression can slow the deterioration of the condition. Some new heart pump devices, including the Sunshine Heart C-Pulse, have even exhibited an ability to reverse heart failure, which is a very attractive feature for younger patients.

“Given the limited options currently available for advanced heart failure treatment, and the substantial population suitable for VAD implantation earlier in disease progression, GlobalData expects to see continued interest in total artificial hearts, along with considerable adoption of VADs by 2016.”

For more information: www.globaldata.com 

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init